MA39342B2 - Anticorps il -21 - Google Patents

Anticorps il -21

Info

Publication number
MA39342B2
MA39342B2 MA39342A MA39342A MA39342B2 MA 39342 B2 MA39342 B2 MA 39342B2 MA 39342 A MA39342 A MA 39342A MA 39342 A MA39342 A MA 39342A MA 39342 B2 MA39342 B2 MA 39342B2
Authority
MA
Morocco
Prior art keywords
antibodies
methods
compositions
antibody
antagonism
Prior art date
Application number
MA39342A
Other languages
English (en)
Other versions
MA39342A1 (fr
Inventor
Julian Davies
Fabio Magrini
Andrea Paula Martin
Neelufar Mozaffarian
Chetankumar Natvarlal Patel
Oliver Schroeder
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA39342A1 publication Critical patent/MA39342A1/fr
Publication of MA39342B2 publication Critical patent/MA39342B2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des anticorps humanisés construits qui ont une forte affinité de liaison pour il -21 humain et qui le neutralisent, des procédés d'utilisation desdits anticorps pour traiter des maladies dans lesquelles l'antagonisme ou la neutralisation des effets d'il -21 est garanti, telles que des maladies auto-immunes, des compositions et des procédés de production par recombinaison des anticorps, et des compositions pharmaceutiques comprenant lesdits anticorps.
MA39342A 2014-03-21 2015-03-13 Anticorps il -21 MA39342B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461968550P 2014-03-21 2014-03-21
PCT/US2015/020383 WO2015142637A1 (fr) 2014-03-21 2015-03-13 Anticorps il -21

Publications (2)

Publication Number Publication Date
MA39342A1 MA39342A1 (fr) 2018-03-30
MA39342B2 true MA39342B2 (fr) 2020-03-31

Family

ID=54141466

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39342A MA39342B2 (fr) 2014-03-21 2015-03-13 Anticorps il -21

Country Status (24)

Country Link
US (1) US9394362B2 (fr)
EP (1) EP3119806B1 (fr)
JP (2) JP6053989B2 (fr)
KR (1) KR101859857B1 (fr)
CN (1) CN106061999B (fr)
AP (1) AP2016009450A0 (fr)
AR (1) AR099625A1 (fr)
AU (1) AU2015231777B2 (fr)
BR (1) BR112016019176A2 (fr)
CA (1) CA2939543C (fr)
CL (1) CL2016002281A1 (fr)
EA (1) EA033335B1 (fr)
EC (1) ECSP16075416A (fr)
ES (1) ES2774422T3 (fr)
IL (1) IL246909A0 (fr)
MA (1) MA39342B2 (fr)
MX (1) MX2016012120A (fr)
MY (1) MY177915A (fr)
NZ (1) NZ722518A (fr)
PE (1) PE20161221A1 (fr)
PH (1) PH12016501820A1 (fr)
SG (1) SG11201606705QA (fr)
TW (1) TWI646105B (fr)
WO (1) WO2015142637A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015244025B2 (en) 2014-04-08 2019-03-21 Boston Pharmaceuticals Inc. Binding molecules specific for IL-21 and uses thereof
EP3368090A1 (fr) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Conjugués de variants d'anticorps anti-facteur d et leurs utilisations
CA3018792C (fr) * 2016-03-31 2023-03-28 Eli Lilly And Company Anticorps contre il-21 et leurs utilisations
US11554131B2 (en) * 2018-05-31 2023-01-17 Glycom A/S Mixture of HMOs for treating autoimmune diseases
WO2020023702A1 (fr) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Nouveaux promédicaments d'il-21 et leurs procédés d'utilisation
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
CA3108282A1 (fr) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Complexes de ciblage musculaire et leurs utilisations pour le traitement de dystrophinopathies
CA3141626A1 (fr) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Nouveaux promedicaments d'il-15 et leurs procedes d'utilisation
US20220289822A1 (en) 2019-08-21 2022-09-15 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
CA3165927A1 (fr) 2020-01-11 2021-07-15 AskGene Pharma, Inc. Nouvelles cytokines masquees et leurs procedes d'utilisation
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
JP2024525608A (ja) 2021-07-09 2024-07-12 ダイン セラピューティクス，インコーポレーテッド ジストロフィン異常症を処置するための筋標的化複合体および製剤
AU2022309238A1 (en) * 2021-07-09 2024-01-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
JP2024525611A (ja) * 2021-07-09 2024-07-12 ダイン セラピューティクス，インコーポレーテッド 筋標的化複合体およびジストロフィノパチーを処置するためのその使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX336813B (es) * 1996-02-09 2016-02-02 Abbvie Biotechnology Ltd Anticuerpos humanos que ligan el tnfa humano.
NZ542306A (en) * 2003-03-14 2008-04-30 Wyeth Corp Antibodies against human IL-21 receptor and uses therefor
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
WO2007111714A2 (fr) * 2005-11-28 2007-10-04 Zymogenetics, Inc. antagonistes de l'IL-21
WO2007114861A2 (fr) * 2005-11-28 2007-10-11 Zymogenetics, Inc. Antagonistes du recepteur de il-21
US20090076249A1 (en) * 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
ME03057B (fr) * 2007-12-07 2019-01-20 Zymogenetics Inc Molécules d'anticorps humanisés spécifiques pour l'IL-31
US7883700B2 (en) * 2007-12-07 2011-02-08 Zymogenetics, Inc. Anti-human IL-21 monoclonal antibodies
WO2012098113A1 (fr) 2011-01-17 2012-07-26 Novo Nordisk A/S Ligands il-21
CN103702721A (zh) * 2011-05-31 2014-04-02 诺沃—诺迪斯克有限公司 Il-21表位和il-21配体

Also Published As

Publication number Publication date
KR101859857B1 (ko) 2018-05-18
CL2016002281A1 (es) 2017-06-23
PH12016501820A1 (en) 2016-11-07
MX2016012120A (es) 2016-12-09
US20150266954A1 (en) 2015-09-24
EP3119806A1 (fr) 2017-01-25
CA2939543C (fr) 2018-01-16
MY177915A (en) 2020-09-25
PE20161221A1 (es) 2016-11-12
JP2016520088A (ja) 2016-07-11
JP6053989B2 (ja) 2017-01-11
JP6373944B2 (ja) 2018-08-15
TWI646105B (zh) 2019-01-01
BR112016019176A2 (pt) 2017-10-10
ES2774422T3 (es) 2020-07-21
NZ722518A (en) 2017-12-22
EP3119806A4 (fr) 2017-11-01
AP2016009450A0 (en) 2016-09-30
EP3119806B1 (fr) 2020-01-01
CN106061999A (zh) 2016-10-26
TW201623330A (zh) 2016-07-01
WO2015142637A1 (fr) 2015-09-24
CN106061999B (zh) 2020-07-31
AR099625A1 (es) 2016-08-03
US9394362B2 (en) 2016-07-19
EA033335B1 (ru) 2019-09-30
CA2939543A1 (fr) 2015-09-24
AU2015231777A1 (en) 2016-08-18
KR20160124166A (ko) 2016-10-26
JP2017093435A (ja) 2017-06-01
EA201691521A1 (ru) 2017-02-28
SG11201606705QA (en) 2016-09-29
IL246909A0 (en) 2016-09-29
AU2015231777B2 (en) 2017-08-03
ECSP16075416A (es) 2018-05-31
MA39342A1 (fr) 2018-03-30

Similar Documents

Publication Publication Date Title
MA39342B2 (fr) Anticorps il -21
WO2018069500A3 (fr) Anticorps anti-lag-3 et compositions
MA42622B1 (fr) Agents de liaison à tigit et leurs utilisations
EP4406554A3 (fr) Formulations d'anticorps anti-cd3
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
WO2018017864A3 (fr) Agents de liaison à pvrig et leurs utilisations
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
MA44322A (fr) Compositions comprenant des souches bactériennes
MA43982A (fr) Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1
MA42471A (fr) Compositions comprenant des souches bactériennes
EA201792047A1 (ru) Новые соединения
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
MA40754B1 (fr) Compositions comprenant des souches bactériennes
MA41060B1 (fr) Compositions comprenant des souches bactériennes
MA55434A (fr) Compositions comprenant des souches bactériennes
MA49726B1 (fr) Formulation d'anticorps anti-cgrp
MA41010B1 (fr) Compositions comprenant des souches bactériennes
MA45125B1 (fr) Anticorps anti-alpha-synucléine et leurs utilisations
WO2015132675A3 (fr) Procédés et compositions pour modifier une réponse immunitaire
EP4696785A3 (fr) Anticorps anti-pd-1
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
WO2017049038A3 (fr) Anticorps anti-cd115
MX2017001038A (es) Variantes de proteina de unión al factor h y metodos de uso de estas.
EP3492096A4 (fr) Composition pharmaceutique pour le traitement de maladies oculaires, contenant une protéine cas9 et un arn guide